The FDA updated tarlatamab-dlle prescribing information, reducing monitoring time after the first two doses for extensive-stage small cell lung cancer.
2
Patients should now be monitored for 6 to 8 hours after the first two infusions, down from the previous 22 to 24 hours.
3
Vital signs assessments are required the day after each of the first two doses, with specific monitoring times for subsequent doses.
4
Tarlatamab is indicated for adults with extensive-stage small cell lung cancer after platinum-based chemotherapy.
5
Cytokine release syndrome occurred in 57% of a pooled safety population, with neurologic toxicity reported in 65% of patients.
